Impact Factor
3.73
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.34
3,143 total citations
h5-index
55
h5 depth signal
Cited share
57.7%
575 of 996
Total citations
3,143
Citation footprint
Metric signal
3.11
External metric anchor
Self-citation
4.6%
145 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,853
Canada
408
China
305
United Kingdom
299
Italy
247
Citing Fields of Research
Inflammatory Bowel Diseases & Infections
4,806
Immunology
655
Digestive Disorders
551
Auto-Inflammatory Disorders
244
Epithelial Barriers
196
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
12,323
Articles tracked across the journal lifetime
Indexed publication set
996
575 cited publications
Last 12 months
455
37.9 publications/month
Open access share
20.7%
94 OA publications in the last year
Leading citing country
United States
1,853 citing publications
Leading citing field
Inflammatory Bowel Diseases & Infections
4,806 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v4n1,spring 1998-
v4n1,spring 1998-
Active Coverage
Research Focus & Classification
Indexed Subjects
Inflammatory Bowel Diseases & Infections
Issuing & Sponsoring Bodies
Contributor
Crohn's & Colitis Foundation of America
Broad Categories
Gastroenterology
Inflammatory Bowel Diseases & Infections
MeSH Descriptors
Colitis, Ulcerative
Crohn Disease
Inflammatory Bowel Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
03
04
05
DOI 10.1093/ibd/izag196
Open DOI
Health-related quality of life after diagnosis of ulcerative colitis and Crohn’s disease: 3-year trajectories and factors associated with clinically meaningful improvement (the IBSEN III cohort)
Background: Evidence for the clinical importance of changes in health-related quality of life (HRQoL) over time in unselected patients with ulcerative colitis (UC) and Crohn’s disease (CD) is limited. We aimed to describe HRQoL trajector...
06
07
DOI 10.1093/ibd/izag198
Open DOI
B cells regulate T cell transfer colitis by partially reconstituting luminal IgA and modulating the colonic microbiota
Loss of immune tolerance to commensal microbial antigens is a central driver of inflammatory bowel disease. While regulatory T cells are well recognized in maintaining intestinal homeostasis, the contribution of B cells—particularly IgA-...
08
09
DOI 10.1093/ibd/izag201
Open DOI
Morganella morganii -derived histamine impairs intestinal barrier function via HRH4 and aggravates colitis
Background: Pro-inflammatory dietary patterns are associated with an increased risk of Crohn’s disease (CD) and shifts in the gut microbiota. Our previous multi-omics analysis had identified the enrichment of Morganella morganii (M. morg...
10
DOI 10.1093/ibd/izag203
Open DOI
Current evidence for first-line advanced therapies in pediatric ulcerative colitis: a critical review
Background: The therapeutic landscape of pediatric ulcerative colitis (UC) has evolved substantially with the introduction of multiple advanced therapies, creating new challenges in selecting the most appropriate initial treatment. While...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Official journal of the Crohn's & Colitis Foundation of America.
Vol. 1, no. 1 (SPRING 1995)19980707 Notice not published Printed on acid-free paper